← Search & browse all drugs

tirofiban

B01AC17

Forms & Strengths

Intravenous injection: 50 mcg/mL (100 mL, 500 mL)
Premixed IV infusion: 25 mcg/mL in 0.9% NaCl (250 mL)

Adult Dosing

Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) / Percutaneous Coronary Intervention (PCI): 25 mcg/kg administered intravenously as a bolus within 5 minutes, followed by maintenance infusion of 0.15 mcg/kg/min.
Severe renal impairment (CrCl < 30 mL/min): Reduce maintenance infusion rate by 50% (0.075 mcg/kg/min).

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established.

Indications

Reduction of rate of thrombotic cardiovascular events in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
Adjunct to percutaneous coronary intervention (PCI) for the prevention of acute ischemic complications.

Mechanism of Action

Reversible antagonist of platelet glycoprotein (GP) IIb/IIIa receptor, the major membrane receptor involved in platelet aggregation.
Inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands.

Contraindications

Active internal bleeding or history of bleeding diathesis within the previous 30 days.
History of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm.
Severe hypersensitivity to tirofiban or any component of the product.
History of thrombocytopenia with prior tirofiban administration.

Adverse Reactions

Bleeding (major and minor hemorrhage, ecchymosis, epistaxis)
Thrombocytopenia (acute, profound)
Nausea
Fever
Headache
Dizziness

Drug Interactions

Anticoagulants (heparin, warfarin, direct oral anticoagulants): Increased risk of major bleeding.
Antiplatelet agents (aspirin, P2Y12 inhibitors like clopidogrel): Increased risk of bleeding.
Thrombolytic agents: Significant potentiation of hemorrhage risk.

Curated Content: Needs Vetting Before Put to Clinical Use